
The White House abruptly pulled the nomination of Dr. Heidi Overton to lead the Food and Drug Administration late on Tuesday, November 17, 2026, the night before a Senate committee was due to vote on whether to advance her. The decision, first reported by Axios and confirmed by a White House official, ended a three-month confirmation fight and left the FDA without a permanent commissioner since May.
The White House pulled Overton's nomination late on Tuesday night, hours before the committee was due to vote on Wednesday, November 18, on sending it to the full Senate. Axios first reported the decision, and a White House official confirmed it, after days of frantic work to shore up support.
The arithmetic had become brutal. Republicans hold 12 of the committee's 23 seats, with Democrats holding 11, so Overton needed every Republican vote if Democrats united against her. Senator Josh Hawley had threatened to sink it, and the anti-abortion movement was furious at the administration's slow pace in restricting mifepristone, the abortion pill.
Republican abortion-rights supporters, including Senators Susan Collins and Lisa Murkowski, had also raised concerns about her record on anti-abortion policies and flavoured vapes. Nominated on August 19 to succeed Marty Makary, who resigned in May, Overton saw her candidacy end without a vote ever being taken.
The Food and Drug Administration is one of the most consequential agencies in American life. Its commissioner shapes how quickly new medicines reach patients, how rigorously vaccines and food are scrutinised, and how it handles contested questions such as abortion medication. Acting commissioner Kyle Diamantas has run the agency since Makary's departure.
Overton's nomination was controversial from the start. Some Republicans questioned her experience, many Democrats opposed her, and prominent supporters of Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again movement lined up against her. Objections centred on vaccines, mifepristone and intrauterine devices, and the FDA is due to complete a mifepristone safety review in March.
The nomination became a proxy fight over the administration's health agenda. Overton spent the past year and a half as the main conduit between health officials advancing MAHA policies and White House officials who stalled them. Though Kennedy praised her nomination in August, insiders described their relationship as "not good" and "icy". "She's not MAHA," one said.
Wednesday's vote was supposed to be the first formal test of whether Overton could survive a panel where the president's party holds only a single-vote advantage. Instead, the White House ended the test before it began. The decision to withdraw rather than fight was striking, because the committee chairman himself believed she could have won.
The collapse also fits a pattern. Overton is the latest health care nominee to be pulled amid crumbling Republican support; the White House has also yanked nominees to lead the Centers for Disease Control and Prevention and the surgeon general's office.
The sharpest reaction came from committee chairman Bill Cassidy, who challenged the decision within hours. "Tonight, the White House abandoned a viable confirmation path for Dr. Overton," he wrote on X. "I believe she would have had the votes to pass out of committee and pass the full Senate." He said pro-life senators had sought final assurances on life issues, and concluded: "The Administration withdrew Dr. Overton rather than make such commitments."
Cassidy had signalled as recently as Sunday that a question mark hung over the nomination. "I don't know that" she has enough votes, he told CBS's "Face the Nation". "I still have questions, and so I cannot tell you the outcome of that vote right now."
Some MAHA advocates celebrated. Vani Hari, known for her "Food Babe" blog, wrote on X: "Another one bites the dust." Calley Means, a MAHA advocate who left the administration in October, had accused Overton of working to "relax standards on fruit flavored vapes". The White House did not immediately comment on the decision or give a timeline for a new nominee.
The fight over Heidi Overton was about more than one nomination. The FDA commissioner decides how quickly new medicines reach patients and how the agency handles its most contested questions. A prolonged vacancy leaves those decisions to acting officials without Senate-confirmed authority.
The episode also exposes the limits of the White House's grip on its own party in the final weeks of Republican Senate control. With Democrats taking the Senate in January, the window for confirming a permanent FDA commissioner under a Republican majority has effectively closed. As Cassidy put it, confirming one will now fall to Senate Democrats.
The immediate question is who the White House names next, and when. Senator Roger Marshall of Kansas, a member of the health committee and an ardent supporter of the administration's Make America Healthy Again policies, has expressed interest in the FDA role, per a person familiar with private discussions.
But it is unclear whether President Trump would pick him, or whether Marshall could win over enough colleagues, given that he has questioned the safety of vaccines in hearings that pitted him against Cassidy and other moderate Republicans. The FDA's mifepristone safety review is due in March, and whoever leads the agency then will face the same pressures that ended Overton's nomination.
Who is Heidi Overton?
Heidi Overton is a board-certified physician and deputy director of the White House Domestic Policy Council, nominated by President Trump in August 2026 to lead the FDA.
Why was her nomination withdrawn?
Senate Republican support was collapsing: anti-abortion conservatives threatened to block her over mifepristone, MAHA supporters opposed her record, and key Republicans stayed undecided.
When was the committee vote supposed to happen?
The Senate Health, Education, Labor and Pensions Committee was set to vote on Wednesday, November 18, 2026. The White House pulled the nomination the night before.
Who is running the FDA now?
Acting commissioner Kyle Diamantas has led the FDA since Marty Makary resigned in May 2026. Senator Roger Marshall has expressed interest, but no new nominee has been announced.
What happens next for the FDA?
The White House must name a new nominee, but Democrats retake the Senate in January, so confirming a permanent commissioner will likely fall to them.
Related coverage: the White House was already weighing dropping Overton before the withdrawal — read the earlier report. US measles cases have surged past 7,700 with 13 deaths in 2026 — read the full report.